Bayer seeks China approval to expand Kerendia use to non-diabetic chronic kidney disease

PUBT · 2d ago
Bayer seeks China approval to expand Kerendia use to non-diabetic chronic kidney disease
  • Bayer filed a new drug application in China to expand Kerendia (finerenone) to adults with non-diabetic chronic kidney disease.
  • The submission to the NMPA’s Center for Drug Evaluation is backed by positive Phase III FIND-CKD results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.